Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14824)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 14, 2017 (publication date) through Jan 29, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(42): 7495-7504 [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i42/7495.htm |
| Number | Citing Articles |
| 1 |
Graziella Rodrigues, Andrea Janz Moreira, Silvia Bona, Elizângela Schemitt, Cláudio Augusto Marroni, Fábio Cangeri Di Naso, Alexandre Simões Dias, Thienne Rocha Pires, Jaqueline Nascimento Picada, Norma Possa Marroni. Simvastatin Reduces Hepatic Oxidative Stress and Endoplasmic Reticulum Stress in Nonalcoholic Steatohepatitis Experimental Model. Oxidative Medicine and Cellular Longevity 2019; 2019: 1 doi: 10.1155/2019/3201873
|
| 2 |
Ahad Eshraghian, Shahrokh Iravani, Pedram Azimzadeh. The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity. Middle East Journal of Digestive Diseases 2018; 10(2): 96 doi: 10.15171/mejdd.2018.97
|
| 3 |
Shuai Xu, Lina Kong, Lin Li, Changyuan Wang, Jiangning Gu, Haifeng Luo, Qiang Meng. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024; 1870(2): 166930 doi: 10.1016/j.bbadis.2023.166930
|
| 4 |
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel, J.A. Velarde-Ruiz Velasco. Consenso mexicano de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2019; 84(1): 69 doi: 10.1016/j.rgmx.2018.11.007
|
| 5 |
Cynthia Barrera, Rodrigo Valenzuela, Miguel A. Rincón, Alejandra Espinosa, Sandra López-Arana, Daniel González-Mañan, Nalda Romero, Romina Vargas, Luis A. Videla. Iron-induced derangement in hepatic Δ-5 and Δ-6 desaturation capacity and fatty acid profile leading to steatosis: Impact on extrahepatic tissues and prevention by antioxidant-rich extra virgin olive oil. Prostaglandins, Leukotrienes and Essential Fatty Acids 2020; 153: 102058 doi: 10.1016/j.plefa.2020.102058
|
| 6 |
Ahad Eshraghian, Saman Nikeghbalian, Kourosh Kazemi, Alireza Shamsaeefar, Bita Geramizadeh, Seyed Ali Malek-Hosseini. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB 2020; 22(4): 521 doi: 10.1016/j.hpb.2019.07.015
|
| 7 |
Fabiola López-Bautista, Varenka J. Barbero-Becerra, María Yolanda Ríos, M. Ángeles Ramírez-Cisneros, Cristell A. Sánchez-Pérez, Martha H. Ramos-Ostos, Misael Uribe, Norberto C. Chávez-Tapia, Eva Juárez-Hernández. Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients. Annals of Hepatology 2020; 19(5): 482 doi: 10.1016/j.aohep.2020.06.008
|
| 8 |
Oren Tirosh, Anna M. Giudetti. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxidative Medicine and Cellular Longevity 2018; 2018(1) doi: 10.1155/2018/2548154
|
| 9 |
Kamyar Asadipooya, Kamran B. Lankarani, Rishi Raj, Mohammadreza Kalantarhormozi. RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease. International Journal of Endocrinology 2019; 2019: 1 doi: 10.1155/2019/2151302
|
| 10 |
Melinda H. Spooner, Donald B. Jump. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children. Current Opinion in Clinical Nutrition & Metabolic Care 2019; 22(2): 103 doi: 10.1097/MCO.0000000000000539
|
| 11 |
Andrea Morán-Costoya, Ana M. Proenza, Magdalena Gianotti, Isabel Lladó, Adamo Valle. Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver–Adipose Tissue Crosstalk. Antioxidants & Redox Signaling 2021; 35(9): 753 doi: 10.1089/ars.2021.0044
|
| 12 |
Ruifang Zhao, Meilin Zhu, Shuang Zhou, Weiyue Feng, Hanqing Chen. Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease. Frontiers in Chemistry 2020; 8 doi: 10.3389/fchem.2020.00407
|
| 13 |
Madlen Matz-Soja. The Molecular Nutrition of Fats. 2019; : 201 doi: 10.1016/B978-0-12-811297-7.00015-9
|
| 14 |
Jiang-Hua Zhou, Jing-Jing Cai, Zhi-Gang She, Hong-Liang Li. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World Journal of Gastroenterology 2019; 25(11): 1307-1326 doi: 10.3748/wjg.v25.i11.1307
|
| 15 |
Naga Swetha Samji, Rajanshu Verma, Krishna Chaitanya Keri, Ashwani K. Singal, Aijaz Ahmed, Mary Rinella, David Bernstein, Manal F. Abdelmalek, Sanjaya K. Satapathy. Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges. Digestive Diseases and Sciences 2019; 64(12): 3413 doi: 10.1007/s10620-019-05716-1
|
| 16 |
P. Barton Duell, Francine K. Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E. Cohen, Jay D. Horton, Gregg S. Pressman, Peter P. Toth. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2022; 42(6) doi: 10.1161/ATV.0000000000000153
|
| 17 |
Jing-ping Zhou, Yan-dan Ren, Qin-yu Xu, Yang Song, Fei Zhou, Mei-Ya Chen, Jing-jing Liu, Li-Gang Chen, Jin-Shui Pan, Elena Grasselli. Obesity‐Induced Upregulation of ZBTB7A Promotes Lipid Accumulation through SREBP1. BioMed Research International 2020; 2020(1) doi: 10.1155/2020/4087928
|
| 18 |
Juan Li, Lv Zhu, Yu-mei Zhang, Huan Chen, Yi-fan Miao, Hong-xin Kang, Hong-yu Ren, Mei-hua Wan, Dan Long, Wen-fu Tang, Caigan Du. Sheng‐Jiang Powder Ameliorates High Fat Diet Induced Nonalcoholic Fatty Liver Disease via Inhibiting Activation of Akt/mTOR/S6 Pathway in Rats. Evidence-Based Complementary and Alternative Medicine 2018; 2018(1) doi: 10.1155/2018/6190254
|
| 19 |
Xue-Yuan Jin, Chuan-Bao Zhu, Shi-Yong Fan, Jia-Lin Sun, Yu-Cong Shi, Chu-Han Wang, Hui-Fen Wang, Bo-Hua Zhong, Yi-Shan Yao, Wei-Guo Shi. Novel hypolipidemic conjugates of fatty acid and bile acid with lysine for linkage. Drug Development and Industrial Pharmacy 2019; 45(6): 995 doi: 10.1080/03639045.2019.1590393
|
| 20 |
Ahad Eshraghian, Saman Nikeghbalian, Bita Geramizadeh, Kourosh Kazemi, Alireza Shamsaeefar, Seyed Ali Malek-Hosseini. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. Clinics and Research in Hepatology and Gastroenterology 2020; 44(4): 572 doi: 10.1016/j.clinre.2019.09.002
|
| 21 |
Adriana Sánchez-García, Amirhossein Sahebkar, Mario Simental-Mendía, Luis E. Simental-Mendía. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacological Research 2018; 135: 144 doi: 10.1016/j.phrs.2018.08.008
|
| 22 |
Omar E. Hegazi, Samer O. Alalalmeh, Ghala Rashid Humaid Alnuaimi, Moyad Shahwan, Ammar Abdulrahman Jairoun, Nasser M. Alorfi, Shaker A. Majrashi, Mustfa Faisal Alkhanani, Abdullah Alkhattabi, Mansour M. Alourfi, Faris A. Alsolami, Saeed Alsharif, Hatim Alshahrani. NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1227046
|
| 23 |
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel, J.A. Velarde-Ruiz Velasco. The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019; 84(1): 69 doi: 10.1016/j.rgmxen.2019.02.003
|
| 24 |
Xuan G. Luong, Sarah K. Stevens, Andreas Jekle, Tse-I Lin, Kusum Gupta, Dinah Misner, Sushmita Chanda, Sucheta Mukherjee, Caroline Williams, Antitsa Stoycheva, Lawrence M. Blatt, Leonid N. Beigelman, Julian A. Symons, Pierre Raboisson, David McGowan, Koen Vandyck, Jerome Deval, Olivier Barbier. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLOS ONE 2020; 15(12): e0240338 doi: 10.1371/journal.pone.0240338
|
| 25 |
Dominic S. Ng. Emerging insight into the role of cellular cholesterol in the pathogenesis of nonalcoholic steatohepatitis progression. Current Opinion in Lipidology 2020; 31(4): 262 doi: 10.1097/MOL.0000000000000693
|
| 26 |
Ming Yue Wang, Kousalya Prabahar, Mihnea‐Alexandru Găman, Jin Lin Zhang. Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta‐analysis on randomized controlled trials. Journal of Digestive Diseases 2023; 24(6-7): 380 doi: 10.1111/1751-2980.13210
|
| 27 |
Abhishek Kulkarni, Sara Ibrahim, Isra Haider, Amina Basha, Emma Montgomery, Ebru Ermis, Raghavendra G. Mirmira, Ryan M. Anderson. A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease. Biomedicines 2022; 10(2): 479 doi: 10.3390/biomedicines10020479
|
| 28 |
Yisa Wang, Peng Ma, Zijing Wang, Mingxia Sun, Biyu Hou, Tianshu Xu, Wenlan Li, Xiuying Yang, Guanhua Du, Tengfei Ji, Guifen Qiang. Uncovering the effect and mechanism of Panax notoginseng saponins on metabolic syndrome by network pharmacology strategy. Journal of Ethnopharmacology 2023; 300: 115680 doi: 10.1016/j.jep.2022.115680
|
| 29 |
Sreeshma Tellapuri, Patrick D. Sutphin, Muhammad S. Beg, Amit G. Singal, Sanjeeva P. Kalva. Staging systems of hepatocellular carcinoma: A review. Indian Journal of Gastroenterology 2018; 37(6): 481 doi: 10.1007/s12664-018-0915-0
|
| 30 |
Ming Li, Qian Wang, Yong Li, Shengtian Cao, Yingjun Zhang, Zhongqing Wang, Guozhu Liu, Jing Li, Baohua Gu. Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges. Pharmacology & Therapeutics 2020; 212: 107539 doi: 10.1016/j.pharmthera.2020.107539
|
| 31 |
April D. Lake, Rhiannon N. Hardwick, Christopher P. Leamon, Philip S. Low, Nathan J. Cherrington. Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. Toxicology and Applied Pharmacology 2019; 368: 49 doi: 10.1016/j.taap.2019.02.009
|
| 32 |
Gehan H. Heeba, Reham M. El-Deen, Rania G. Abdel-latif, Mohamed M.A. Khalifa. Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. Canadian Journal of Physiology and Pharmacology 2020; 98(8): 498 doi: 10.1139/cjpp-2019-0487
|
| 33 |
Hiromi Chikada, Kinuyo Ida, Yuji Nishikawa, Yutaka Inagaki, Akihide Kamiya. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-66539-z
|
| 34 |
Yeonhwa Song, Sanghwa Kim, Jinyeong Heo, David Shum, Su-Yeon Lee, Minji Lee, A-Ram Kim, Haeng Ran Seo. Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-90263-x
|
| 35 |
Fereshteh Asgharzadeh, Maryam Moradi Binabaj, Sahar Fanoudi, William C. Cho, Yu-jeong Yang, Maryam Azarian, Mehdi Shafiee Ardestani, Nasim Nasiri, Marzieh Ramezani Farani, Yun Suk Huh. Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities. Advanced Pharmaceutical Bulletin 2024; 14(3): 513 doi: 10.34172/apb.2024.061
|
| 36 |
Minhua Lin, Huamin Zeng, Guiqing Deng, Jiapei Lei, Jinxin Li. Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2021; 45(3): 101530 doi: 10.1016/j.clinre.2020.08.008
|
| 37 |
Simiao Zhang, Sheng Zheng, Ya Li, Juan Yang, Xiaozhou Mao, Tao Liu, Qiuxin Zhang, ZhiPeng Fu, Xing Zhu, Long Xu. Protective effects of syringic acid in nonalcoholic fatty liver in rats through regulation of Nrf2/HO‐1 signaling pathway. Journal of Biochemical and Molecular Toxicology 2024; 38(9) doi: 10.1002/jbt.23809
|
| 38 |
Milica Culafic, Sandra Vezmar Kovacevic, Violeta Dopsaj, Branislav Oluic, Nemanja Bidzic, Branislava Miljkovic, Djordje Culafic. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. Journal of Medical Biochemistry 2019; 0(0) doi: 10.2478/jomb-2019-0043
|
| 39 |
Seung Ho Jeon, Eungyeong Jang, Geonha Park, Yeongae Lee, Young Pyo Jang, Kyung-Tae Lee, Kyung-Soo Inn, Jong Kil Lee, Jang-Hoon Lee. Beneficial Activities of Alisma orientale Extract in a Western Diet-Induced Murine Non-Alcoholic Steatohepatitis and Related Fibrosis Model via Regulation of the Hepatic Adiponectin and Farnesoid X Receptor Pathways. Nutrients 2022; 14(3): 695 doi: 10.3390/nu14030695
|
| 40 |
Komal Thapa, Ajmer Singh Grewal, Neha Kanojia, Lata Rani, Neelam Sharma, Sukhbir Singh. Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development. Current Drug Discovery Technologies 2021; 18(3): 333 doi: 10.2174/1570163817666200121143959
|
| 41 |
Gen-shen Cai, Hui Su, Jing Zhang. Protective effect of probiotics in patients with non-alcoholic fatty liver disease. Medicine 2020; 99(32): e21464 doi: 10.1097/MD.0000000000021464
|
| 42 |
Ahad Eshraghian, Alireza Taghavi, Hamed Nikoupour, Saman Nikeghbalian, Seyed Ali Malek-Hosseini. Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02781-9
|
| 43 |
Eun-Yong Choi, Jin Ouk Choi, Chan Young Park, Seon-Hee Kim, Donghyun Kim. Water Extract of Artemisia annua L. Exhibits Hepatoprotective Effects Through Improvement of Lipid Accumulation and Oxidative Stress-Induced Cytotoxicity. Journal of Medicinal Food 2020; 23(12): 1312 doi: 10.1089/jmf.2020.4696
|
| 44 |
Xiaoru Huang, Xuening Liu, Zijian Li. Bile acids and coronavirus disease 2019. Acta Pharmaceutica Sinica B 2024; 14(5): 1939 doi: 10.1016/j.apsb.2024.02.011
|